000 | 01940 a2200553 4500 | ||
---|---|---|---|
005 | 20250513142017.0 | ||
264 | 0 | _c19980610 | |
008 | 199806s 0 0 eng d | ||
022 | _a0303-6995 | ||
024 | 7 |
_a10.1007/978-3-7091-6499-0_14 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aNaoi, M | |
245 | 0 | 0 |
_aOxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. _h[electronic resource] |
260 |
_bJournal of neural transmission. Supplementum _c1998 |
||
300 |
_a125-38 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_a3,4-Dihydroxyphenylacetic Acid _xmetabolism |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntioxidants _xpharmacology |
650 | 0 | 4 |
_aCorpus Striatum _xdrug effects |
650 | 0 | 4 |
_aCycloheximide _xpharmacology |
650 | 0 | 4 | _aDNA Damage |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 |
_aDopamine _xmetabolism |
650 | 0 | 4 |
_aHomovanillic Acid _xmetabolism |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHydroxyl Radical _xmetabolism |
650 | 0 | 4 |
_aIsoquinolines _xmetabolism |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aNecrosis |
650 | 0 | 4 | _aNeuroblastoma |
650 | 0 | 4 |
_aNeurons _xdrug effects |
650 | 0 | 4 |
_aNeurotoxins _xpharmacokinetics |
650 | 0 | 4 |
_aOxidative Stress _xdrug effects |
650 | 0 | 4 |
_aParkinson Disease, Secondary _xchemically induced |
650 | 0 | 4 | _aPosture |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Wistar |
650 | 0 | 4 |
_aSalsoline Alkaloids _xchemical synthesis |
650 | 0 | 4 | _aStereoisomerism |
650 | 0 | 4 |
_aSubstantia Nigra _xdrug effects |
650 | 0 | 4 | _aTetrahydroisoquinolines |
650 | 0 | 4 | _aTumor Cells, Cultured |
700 | 1 | _aMaruyama, W | |
700 | 1 | _aKasamatsu, T | |
700 | 1 | _aDostert, P | |
773 | 0 |
_tJournal of neural transmission. Supplementum _gvol. 52 _gp. 125-38 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/978-3-7091-6499-0_14 _zAvailable from publisher's website |
999 |
_c9531685 _d9531685 |